Nanostructured Drug Delivery Systems in Infectious Disease Treatment

1st Edition - July 12, 2024
Editors: Sarwar Beg, Rahul Shukla, Mayank Handa, Mahfoozur Rahman, Ashish Dhir
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 3 3 7 - 4
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 3 3 6 - 7

Nanostructured Drug Delivery Systems in Infectious Disease Treatment explores a broad range of promising approaches for the treatment of infectious diseases using the latest ad… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Nanostructured Drug Delivery Systems in Infectious Disease Treatment explores a broad range of promising approaches for the treatment of infectious diseases using the latest advancements in nanomedical technologies. The book opens with an introduction about infectious diseases and global burdens. There is also specific discussion and assessment of the global impact of viruses with an emphasis on COVID-19, Zika, and Ebola. Subsequent chapters provide detailed information about various novel nanotherapeutic strategies used for delivering drugs for the treatment of various types of viral, bacterial, and fungal disorders. This will be a valuable resource for graduates, researchers, industry professionals, and anyone working to tackle the challenges of delivering drugs in a more targeted and efficient manner for the treatment of infectious diseases.

Cover image
Title page
Table of Contents
Copyright
Dedication
List of contributors
Preface
Chapter 1. Infectious diseases and its global epidemiology
Abstract
1.1 Introduction
1.2 Emerging and neglected tropical infectious disease
1.3 Conclusions
References
Chapter 2. Impact assessment of virus globally: special emphasis on COVID-19, Zika, and Ebola virus
Abstract
2.1 Introduction
2.2 Health impact
2.3 Global impact of Zika virus
2.4 Global impact of the Ebola virus
2.5 Learning for future challenges
2.6 Conclusion
References
Chapter 3. Nanocombinational therapies for infectious disorders
Abstract
3.1 Introduction
3.2 Nanoparticle system
3.3 Multidrug delivery system for combinational therapy
3.4 Hurdles for codelivery of multiple antiinfectious agents in nanoplatform
3.5 Conclusion
References
Chapter 4. Stimuli responsive nanotechnological advancements in infectious disorders
Abstract
4.1 Introduction
4.2 Infectious disorders
4.3 Nanotechnology in pharmaceutical research
4.4 Stimuli-responsive nanotechnologies in drug delivery
4.5 Nanotechnology for infectious disorders
4.6 Conclusion and future scope
References
Chapter 5. Application of nanotechnology based therapy against malaria
Abstract
5.1 Introduction
5.2 Life cycle of malaria
5.3 Symptoms and disease complications in severe malaria
5.4 Nanoformulation in malaria
5.5 Conclusion and future perspective
Competing interests
Author contributions
Data availability statement
Consent for publication
Acknowledgments
References
Chapter 6. Therapeutic potential of nano assisted delivery in tuberculosis and its management
Abstract
6.1 Introduction
6.2 Conventional treatment options and its limitations
6.3 Routes of administration for nanoassisted delivery systems
6.4 Nanoassisted delivery systems in antituberculosis drugs
6.5 Biofilm penetration as novel strategy to cure tuberculosis
6.6 Nanoassisted drug delivery system in drug-resistant tuberculosis
6.7 Nanoassisted drug delivery system for host-directed therapies
6.8 Stimuli-responsive nanomaterials
6.9 Conclusion
References
Chapter 7. Exploration of advanced therapeutics for lymphatic and cutaneous leishmaniasis
Abstract
7.1 Introduction
7.2 Classification of leishmaniasis
7.3 Current therapeutics available and challenges for leishmania
7.4 Advanced therapeutics for lymphatic and cutaneous leishmania
7.5 Nanotechnology-mediated vaccines
7.6 Preclinical status and status of advanced therapeutics
7.7 Clinical studies
7.8 Future prospects
7.9 Conclusion
Acknowledgment
Conflict of interest
References
Chapter 8. Onychomycosis with current treatment approaches: emergence of niosomes in its effective treatment
Abstract
8.1 Introduction
8.2 Currently available therapy for onychomycosis
8.3 The emergence of niosomes in its effective treatment
8.4 Application of niosomes in onychomycosis
8.5 Conclusion
References
Chapter 9. Nanoantibiotics driven approaches as an advanced therapy for bacterial infections and chemotherapeutic resistance
Abstract
9.1 Introduction
9.2 Development of drug resistance and failure of therapeutic regimen
9.3 Nanoantibiotics against bacterial and chemotherapeutic resistance
9.4 Nanomaterial for advanced therapies
9.5 Emerging nanoantibiotics for antimicrobial activity
9.6 Evaluative analysis between antibiotics and nanoantibiotics
9.7 Conclusion and future perspectives
Competing interests
Author contributions
Data Availability Statement
Consent for publication
Acknowledgments
References
Chapter 10. Role of biotechnology as a theranostic tool in infectious diseases
Abstract
10.1 Introduction
10.2 Types of theranostic tools
10.3 Applications and limitations of theranostic tools
10.4 Future directions and conclusions
References
Chapter 11. Nanomedicine in infectious disease challenges and regulatory concerns
Abstract
11.1 Introduction
11.2 Infectious diseases
11.3 Challenges associated with the treatment of infectious diseases
11.4 Drug delivery and associated challenges in infectious diseases
11.5 Strategies to deal with the challenges
11.6 Nanomedicine in the treatment of infectious diseases
11.7 Types and properties of nanomaterial used in the preparation of nanomedicine
11.8 Nanoparticles in infectious diseases
11.9 The need for nanomedicine regulation
11.10 The regulatory challenges for nanomedicine
11.11 Global strategies for nanomedicine regulation
11.12 Conclusion and future prospective
References
Chapter 12. Role of nanotechnology derived natural products as potential therapeutics against infectious disease
Abstract
12.1 Introduction
12.2 Outlook on infectious diseases
12.3 Natural products against combating infections
12.4 Nanotechnology and associated advantages
12.5 Role of nanotechnology based natural products
12.6 Conclusion, future perspective, and challenges
References
Further reading
Chapter 13. Nanotechnology: a nanotherapeutics approach to counteracting brain infection
Abstract
13.1 Introduction
13.2 Brain infections: types and challenges
13.3 Nanotechnology in medicine
13.4 Nanoparticles for drug delivery
13.5 Targeted nanotherapeutics
13.6 Imaging and diagnosis
13.7 Enhanced antibiotics and antimicrobial agents
13.8 Immunomodulation and brain infections
13.9 Biofilm disruption
13.10 Neuroprotection and recovery
13.11 Safety and ethical considerations
13.12 Future directions and challenges
13.13 Conclusion
References
Chapter 14. Recent advances in nanomedicines for the treatment of global infectious diseases
Abstract
14.1 Introduction
14.2 Different types of infections
14.3 Classification of bacterial, viral, and fungal pathogens
14.4 Drug resistance
14.5 Nanotechnology to improve the antimicrobial delivery
14.6 Difficulties in treating infectious and ailments using nanotechnology
14.7 Targeted treatment of diseases utilizing nanoparticles
14.8 Conclusion
References
Chapter 15. Transferosomes drug delivery in topical infectious disorders
Abstract
15.1 Introduction
15.2 Composition of transferosomes
15.3 Advantages and disadvantages of transferomes
15.4 Mechanism of action
15.5 Ideal characteristics of transferosomes
15.6 Preparation techniques for transferosomes
15.7 Optimization of formulation containing transferosomes
15.8 Characterization of transferosomes
15.9 Application of transferesomes in topical infectious disorder
15.10 Conclusion
Conflicts of interest
Reference
Chapter 16. Graphene and its nanocomposites as antimicrobial potential in topical disease: state of the art
Abstract
16.1 Introduction
16.2 Pathophysiology
16.3 Graphene oxide
16.4 Nanotechnology
16.5 Role of graphene and graphene oxide nanocomposites as antimicrobial potential
16.6 Conclusion
References
Chapter 17. Natural seed oil-loaded emulgel/nanogel in topical infectious disorders
Abstract
17.1 Introduction
17.2 Topical infectious disease
17.3 Phytoconstituents
17.4 Role of natural oil-loaded nanoemulsion/nanogel in topical infectious disease
17.5 Conclusion
References
Chapter 18. Role of ferulic acid as nanomedicine in the management of various diseases
Abstract
18.1 Introduction
18.2 Metabolism of ferulic acid
18.3 Ferulic acid (scavenger of nascent oxygen and free radicals)
18.4 Ferulic acid loaded with nanoparticles
18.5 Conclusion
References
Chapter 19. Emergence of nano-based system for effective delivery of flavonoids against topical infectious disorders
Abstract
19.1 Introduction
19.2 Mechanism of action of flavonoid in topical infection
19.3 Bioavailability and toxicity of flavonoids
19.4 Why nanoencapsulation is necessary for cutaneous flavonoid delivery
19.5 Nanocarriers in their effective delivery against topical infectious disorders
19.6 Conclusion
References
Chapter 20. Key role of secondary metabolites in topical infectious disorders: nanomedicine in its effective delivery
Abstract
20.1 Introduction
20.2 Challenges for topical drug application
20.3 Secondary metabolites
20.4 Nanocarrier as effective delivery of secondary metabolites for topical infection
20.5 Nanotoxicology
20.6 Conclusion
References
Chapter 21. Nanocrystals as topical applications: state of the art
Abstract
21.1 Introduction
21.2 Drug delivery through the skin
21.3 Mechanism
21.4 Potential of a nanocrystal
21.5 Nanocrystal carrier system for topically active agents
21.6 Toxicity of nanocrystals
21.7 Conclusion
References
Index

Sarwar Beg

Sarwar Beg, PhD is currently serving as AMS-DBT Newton International Fellow at University of Central Lancashire, UK, and working in the area of glioblastoma research using targeted nanomedicines. He is also serving as the Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. He has over a decade of teaching and research experience in the field of pharmaceutics and biopharmaceutics, especially in the development of novel and nanostructured drug delivery systems using Quality-by-Design paradigms with core expertise in computational pharmaceutics, experimental designs and multivariate statistical techniques. He has authored over 200 publications, 60 book chapters, 15 books, 03 Indian patent applications and H-Index of 40 with over 5400 citations to his credit.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India

Rahul Shukla

Dr. Rahul Shukla is currently working as an Assistant Professor (Contract) at Department of Pharmaceutics, NIPER Raebareli, India, He has a PhD in Pharmaceutical Sciences from CSIR CDRI and J.N.U New Delhi, India, an M.Pharm from IIT BHU,Varanasi, India and B.Pharm from Jamia Hamdard, New Delhi. He has more than ten years of research and academic experience with more than 30 publications and 10 book chapters to his credit. He has filed 7 Indian Patent and 1 Copyright. Recently he has edited a book on the Role of Novel Drug Delivery Vehicles in Nanobiomedicine. His current research interests include targeted drug delivery systems, particle engineering, controlled delivery for neurodegenerative diseases, dendrimer mediated drug delivery, solubilization and bioavailability enhancements.

Affiliations and expertise

Assistant Professor, Department of Pharmeceutics, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh, India

Mayank Handa

Mr. Mayank Handa, has completed his B. Pharm and M. Pharm from U.I.P.S, Panjab University, Chandigarh India. Currently, pursuing as Ph.D. at National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow UP. His past industrial experience includes working at Eisai India Limited, India and Themis Medicare Limited, India. He has more than 20 peer reviewed publications in journals international repute and 10 book chapter. He has filed 5 Indian patent and 1 Copyright. His research interests in polymeric nanoparticles and emulsion based drug delivery, targeted drug delivery systems, Intranasal and transdermal drug delivery.

Affiliations and expertise

National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India

Mahfoozur Rahman

Mahfoozur Rahman is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. He has authored more than 130 publications in peer-reviewed journals, 30 book chapters, seven books, and four articles in international magazines with various publishers. He has a Google Scholar h-index of 27 and over 1700 citations to his credit. He also serves on the editorial boards and as guest editor for several journals. He has received travel grants from various international congresses, such as IAPRD, MDS, Nano Today, KSN and WCN, on the basis of his research work and contribution in the field.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, India

Ashish Dhir

Dr. Ashish Dhir is an Associate Principal Scientist in Drug Discovery for Merck in New Jersey. He was previously a Senior Scientist in the Department of Neurology, School of Medicine, University of California, Davis in Sacramento. He received his doctorate in Pharmacology from Panjab University, Chandigarh, India. He has over 15 years of experience in preclinical research in the field of neurological and neuropsychiatric disorders. Dr. Dhir's research entails establishing and validating animal models of various disease conditions, as well as investigating novel drugs and targets for disease treatment. Dr. Dhir has over 90 peer-reviewed journal papers and serves as an ad hoc reviewer and on the Editorial Board of several prestigious journals. He was recently named to the list of the world's top 2% pharmacology scientists (ranking 1053 out of 94611). Dr. Dhir has received numerous honors, including the Rafaelsen Young Investigator Award from the Collegium International Neuropsychopharmacologicum (CINP).

Affiliations and expertise

Associate Principal Scientist- Drug Discovery, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Nanostructured Drug Delivery Systems in Infectious Disease Treatment

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Sarwar Beg

Rahul Shukla

Mayank Handa

Mahfoozur Rahman

Ashish Dhir